• "Biotech where science and spirit meet..."
Skip to content

{ Category Archives: } Biotech (General)

Oligomerix to Present at BIO CEO & Investor Conference, TAU2020 Global Conference

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO &…

Targeting Amyloid Oligomers for Alzheimer’s Research

Alzheimer’s disease is one of the most frightening diseases people can face. The deterioration of memory and comprehension and, ultimately death, is a terrifying concept. And little headway has been made in developing a treatment for this disease. But that could be changing. Biogen is likely on the road to having aducanumab approved as a…

BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO and President, will provide an update of the Company’s ALS and MS trials and company growth strategy at The BIO CEO & Investor Conference, being held…

Salk scientists link rapid brain growth in autism to DNA damage

LA JOLLA–(January 30, 2020) Researchers at the Salk Institute have discovered a unique pattern of DNA damage that arises in brain cells derived from individuals with a macrocephalic form of autism spectrum disorder (ASD). The observation, published in the journal Cell Stem Cell, helps explain what might go awry in the brain during cell division and…

BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office (EPO) has communicated its intention to grant a European patent titled ‘Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors’. Allowed claims cover the method for manufacturing…

Bausch Health Companies (BHC) Receives a Buy from Barclays

In a report issued on January 24, Balaji Prasad from Barclays maintained a Buy rating on Bausch Health Companies (BHC – Research Report), with a price target of $33.00. The company’s shares closed last Monday at $28.40. According to TipRanks.com, Prasad is a 4-star analyst with an average return of 16.6% and a 70.0% success rate. Prasad covers the Healthcare sector, focusing on stocks…

Research Drug ‘chaperone’ fends off Alzheimer’s in mice by preventing toxic protein clumping

Alzheimer’s disease has long been associated with the harmful proteins amyloid beta and tau. They clump up in the brain, disrupting neurons and causing memory loss and other symptoms. Researchers at Temple University’s Lewis Katz School of Medicine say they’ve found a new way to prevent amyloid beta and tau from building up in the…

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 billion

– The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price – Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual therapy to lower LDL cholesterol, has potential to transform treatment of cardiovascular…

Attack of the Clones? Memory CD8+ T Cells Stalk the AD, PD Brain

“This beautiful study shows, for the first time, a close association between T cells, cognition, and neurodegenerative disease in humans,” wrote Jonathan Kipnis of University of Virginia in Charlottesville. “These elegant findings on expansion of Epstein-Barr virus-reactive CD8 T cells in the CSF of AD patients are extremely interesting and intriguing,” he added. More at:…

Regeneron drug reduces bone growth for patients with ultra-rare skeletal disease

Patients with the ultra-rare disease FOP grow bone where it doesn’t belong, creating a life-threatening second skeleton. Regeneron Pharmaceuticals believes it can offer hope: A new treatment reduced new bone growth by 90% in a clinical trial, the company said, a result that could lead to Food and Drug Administration approval. More at:  https://www.statnews.com/2020/01/09/regeneron-drug-reduces-bone-growth-rare-skeletal-disease/